Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue

Richard Kennedy, M. Bylesjo, Deborah Kerr, T. Davison, J.M. Black, E.W. Kay, R.J. Holt, V. Proutski, M. Ahdesmaki, V. Farztdinov, N. Goffard, P. Hey, F. McDyer, K. Mulligan, Julie Mussen, E. O'Brien, G. Oliver, S.M. Walker, Jude Mulligan, C. WilsonA. Winter, D. O'Donoghue, H. Mulcahy, J. O'Sullivan, K. Sheahan, J. Hyland, R. Dhir, O.F. Bathe, O. Winqvist, U. Manne, C. Shanmugam, S. Ramaswamy, E.J. Leon, W.I. Smith, Ultan McDermott, Richard Wilson, Daniel Longley, J. Marshall, R. Cummins, D.J. Sargent, Patrick Johnston, Paul Harkin

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Purpose: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray-based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. Patients and Methods: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. Results: The 634-probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P <.001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P <.001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P <.001). Conclusion: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples. © 2011 by American Society of Clinical Oncology.
Original languageEnglish
Pages (from-to)4620-4626
Number of pages7
JournalJournal of Clinical Oncology
Volume29
Issue number35
DOIs
Publication statusPublished - 10 Dec 2011

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue'. Together they form a unique fingerprint.

  • Impacts

    Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation

    Richard Kennedy (Participant), Paul Harkin (Participant), Patrick Johnston (Participant), Alison Hosey (Participant), Julia Miskelly (Participant), Margaret Murray (Participant), Jennifer Quinn (Participant), Colin James (Participant), Jude Mulligan (Participant), Peter Daly (Participant), Paul Mullan (Participant), Julie Mussen (Participant), Ultan McDermott (Participant), Richard Wilson (Participant) & Daniel Longley (Participant)

    Impact: Health Impact, Quality of Life Impact

    Cite this

    Kennedy, R., Bylesjo, M., Kerr, D., Davison, T., Black, J. M., Kay, E. W., Holt, R. J., Proutski, V., Ahdesmaki, M., Farztdinov, V., Goffard, N., Hey, P., McDyer, F., Mulligan, K., Mussen, J., O'Brien, E., Oliver, G., Walker, S. M., Mulligan, J., ... Harkin, P. (2011). Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue. Journal of Clinical Oncology, 29(35), 4620-4626. https://doi.org/10.1200/JCO.2011.35.4498